<DOC>
	<DOCNO>NCT00152230</DOCNO>
	<brief_summary>This control study design compare relapse-free survival overall survival patient receive UFT patient receive surgery alone . Patients randomly assign surgery alone surgery follow UFT within 6 week curative resection . To assess treatment efficacy , data recurrence survival collect 5 year enrollment last patient . To evaluate safety , data adverse event collect 12 month start treatment.Evaluations separately do colon cancer rectal cancer .</brief_summary>
	<brief_title>A Randomized Controlled Study Postoperative Adjuvant Chemotherapy Uracil- Tegafur ( UFT ) Compared With Surgery Alone ( NSAS-CC )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Age 20 75 Performance status 0 , 1 , 2 ( ECOG ) Hematopoietic WBC ≥ 4,000/mm^3 Platelet ≥ 100,000/mm^3 Hepatic AST ALT ≤ 2 time upper limit normal ( ULN ) Total bilirubin ≤ 1.2mg/dL Renal BUN ≤ 25mg/dL Creatinine ≤ 1.5mg/dL Prior anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Colorectal Cancer</keyword>
</DOC>